These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2958866)

  • 1. Local administration of interleukin-2 activates lymphocytes from tumor bearing mice to recruit host immunoreactivity and inhibit tumor growth.
    Forni G; Musso T; Santoni A; Giovarelli M
    Prog Clin Biol Res; 1987; 244():105-14. PubMed ID: 2958866
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo generation, enhancement and recruitment of host cellular immune responses against tumor: influence of MHC antigen expression on clones of tumor cell variants.
    Fernández-Cruz E; Pérez M; Zabay JM; Garrido F
    Prog Clin Biol Res; 1987; 244():115-25. PubMed ID: 2958867
    [No Abstract]   [Full Text] [Related]  

  • 3. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.
    Forni G; Giovarelli M; Santoni A
    J Immunol; 1985 Feb; 134(2):1305-11. PubMed ID: 3871210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro reeducated T helper cells from sarcoma-bearing mice inhibit sarcoma growth in vivo.
    Forni G; Giovarelli M
    J Immunol; 1984 Jan; 132(1):527-33. PubMed ID: 6228583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An approach for the generation of effector lymphocytes from tumor-bearing hosts for the adoptive immunotherapy of established tumors.
    Shu SY; Chou T
    Prog Clin Biol Res; 1987; 244():27-37. PubMed ID: 3498953
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanistic aspects of successful immunotherapy of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2.
    Mulé JJ; Rosenberg SA
    Prog Clin Biol Res; 1987; 244():79-91. PubMed ID: 3310006
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors.
    Grimm EA
    Prog Clin Biol Res; 1987; 244():185-95. PubMed ID: 3498948
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
    Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
    Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunotherapy of malignant tumors with subpopulations of T lymphocytes].
    Fernández-Cruz E
    Rev Esp Oncol; 1982; 29(4):701-10. PubMed ID: 6242320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
    Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
    Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
    Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Mulé JJ
    Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RCS tumor-host interactions: tumor growth dependence on L3T4+ T cells and its regulation by suppressor cells.
    Ohnishi K; Bonavida B
    Prog Clin Biol Res; 1987; 244():359-68. PubMed ID: 2958874
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
    Rosenberg SA; Lotze MT
    Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.